1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
1.8. Key Benefits to the stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. ANTIMALARIAL DRUGS MARKET BY DRUG CLASS
5.1. Introduction
5.2. Quinine
5.2.1. Market Trends and Opportunities
5.2.2. Growth Prospects
5.3. Chloroquine
5.3.1. Market Trends and Opportunities
5.3.2. Growth Prospects
5.4. Proguanil
5.4.1. Market Trends and Opportunities
5.4.2. Growth Prospects
5.5. Mefloquine
5.5.1. Market Trends and Opportunities
5.5.2. Growth Prospects
5.6. Pyrimethamine
5.6.1. Market Trends and Opportunities
5.6.2. Growth Prospects
5.7. Others
5.7.1. Market Trends and Opportunities
5.7.2. Growth Prospects
6. ANTIMALARIAL DRUGS MARKET BY MALARIA TYPE
6.1. Introduction
6.2. Plasmodium falciparum
6.2.1. Market Trends and Opportunities
6.2.2. Growth Prospects
6.3. Plasmodium vivax
6.3.1. Market Trends and Opportunities
6.3.2. Growth Prospects
6.4. Plasmodium malariae
6.4.1. Market Trends and Opportunities
6.4.2. Growth Prospects
6.5. Plasmodium ovale
6.5.1. Market Trends and Opportunities
6.5.2. Growth Prospects
7. ANTIMALARIAL DRUGS MARKET BY MECHANISM OF ACTION
7.1. Introduction
7.2. Treatment for Malaria
7.2.1. Market Trends and Opportunities
7.2.2. Growth Prospects
7.3. Prevention of Malaria
7.3.1. Market Trends and Opportunities
7.3.2. Growth Prospects
8. ANTIMALARIAL DRUGS MARKET BY DISTRIBUTION CHANNEL
8.1. Introduction
8.2. Veterinary Hospitals
8.2.1. Market Trends and Opportunities
8.2.2. Growth Prospects
8.3. Hospital Pharmacy
8.3.1. Market Trends and Opportunities
8.3.2. Growth Prospects
8.4. Retail Pharmacy
8.4.1. Market Trends and Opportunities
8.4.2. Growth Prospects
8.5. E-Commerce
8.5.1. Market Trends and Opportunities
8.5.2. Growth Prospects
8.6. Others
8.6.1. Market Trends and Opportunities
8.6.2. Growth Prospects
9. ANTIMALARIAL DRUGS MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. By Drug Class
9.2.2. By Malaria Type
9.2.3. By Mechanism of Action
9.2.4. By Distribution Channel
9.2.5. By Country
9.2.5.1. United States
9.2.5.1.1. Market Trends and Opportunities
9.2.5.1.2. Growth Prospects
9.2.5.2. Canada
9.2.5.2.1. Market Trends and Opportunities
9.2.5.2.2. Growth Prospects
9.2.5.3. Mexico
9.2.5.3.1. Market Trends and Opportunities
9.2.5.3.2. Growth Prospects
9.3. South America
9.3.1. By Drug Class
9.3.2. By Malaria Type
9.3.3. By Mechanism of Action
9.3.4. By Distribution Channel
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.1.1. Market Trends and Opportunities
9.3.5.1.2. Growth Prospects
9.3.5.2. Argentina
9.3.5.2.1. Market Trends and Opportunities
9.3.5.2.2. Growth Prospects
9.3.5.3. Others
9.3.5.3.1. Market Trends and Opportunities
9.3.5.3.2. Growth Prospects
9.4. Europe
9.4.1. By Drug Class
9.4.2. By Malaria Type
9.4.3. By Mechanism of Action
9.4.4. By Distribution Channel
9.4.5. By Country
9.4.5.1. United Kingdom
9.4.5.1.1. Market Trends and Opportunities
9.4.5.1.2. Growth Prospects
9.4.5.2. Germany
9.4.5.2.1. Market Trends and Opportunities
9.4.5.2.2. Growth Prospects
9.4.5.3. France
9.4.5.3.1. Market Trends and Opportunities
9.4.5.3.2. Growth Prospects
9.4.5.4. Italy
9.4.5.4.1. Market Trends and Opportunities
9.4.5.4.2. Growth Prospects
9.4.5.5. Spain
9.4.5.5.1. Market Trends and Opportunities
9.4.5.5.2. Growth Prospects
9.4.5.6. Others
9.4.5.6.1. Market Trends and Opportunities
9.4.5.6.2. Growth Prospects
9.5. Middle East and Africa
9.5.1. By Drug Class
9.5.2. By Malaria Type
9.5.3. By Mechanism of Action
9.5.4. By Distribution Channel
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.1.1. Market Trends and Opportunities
9.5.5.1.2. Growth Prospects
9.5.5.2. UAE
9.5.5.2.1. Market Trends and Opportunities
9.5.5.2.2. Growth Prospects
9.5.5.3. Others
9.5.5.3.1. Market Trends and Opportunities
9.5.5.3.2. Growth Prospects
9.6. Asia Pacific
9.6.1. By Drug Class
9.6.2. By Malaria Type
9.6.3. By Mechanism of Action
9.6.4. By Distribution Channel
9.6.5. By Country
9.6.5.1. Japan
9.6.5.1.1. Market Trends and Opportunities
9.6.5.1.2. Growth Prospects
9.6.5.2. China
9.6.5.2.1. Market Trends and Opportunities
9.6.5.2.2. Growth Prospects
9.6.5.3. India
9.6.5.3.1. Market Trends and Opportunities
9.6.5.3.2. Growth Prospects
9.6.5.4. South Korea
9.6.5.4.1. Market Trends and Opportunities
9.6.5.4.2. Growth Prospects
9.6.5.5. Taiwan
9.6.5.5.1. Market Trends and Opportunities
9.6.5.5.2. Growth Prospects
9.6.5.6. Thailand
9.6.5.6.1. Market Trends and Opportunities
9.6.5.6.2. Growth Prospects
9.6.5.7. Indonesia
9.6.5.7.1. Market Trends and Opportunities
9.6.5.7.2. Growth Prospects
9.6.5.8. Others
9.6.5.8.1. Market Trends and Opportunities
9.6.5.8.2. Growth Prospects
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Novartis International AG
11.2. GlaxoSmithKline plc
11.3. Sanofi
11.4. Pfizer Inc
11.5. Cipla Limited
11.6. Mylan NV
11.7. Ipca Laboratories Limited